CA2228314A1 - Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases - Google Patents

Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases Download PDF

Info

Publication number
CA2228314A1
CA2228314A1 CA002228314A CA2228314A CA2228314A1 CA 2228314 A1 CA2228314 A1 CA 2228314A1 CA 002228314 A CA002228314 A CA 002228314A CA 2228314 A CA2228314 A CA 2228314A CA 2228314 A1 CA2228314 A1 CA 2228314A1
Authority
CA
Canada
Prior art keywords
pde
acid
inhibitors
treatment
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002228314A
Other languages
English (en)
French (fr)
Inventor
Michael Carsten Truss
Stefan Uckert
Christian Georg Stief
Wolf-Georg Forssmann
Udo Jonas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FROSSMANN WOLF-GEORG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2228314A1 publication Critical patent/CA2228314A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CA002228314A 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases Abandoned CA2228314A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19529102.6 1995-08-08
DE19529102A DE19529102A1 (de) 1995-08-08 1995-08-08 Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen

Publications (1)

Publication Number Publication Date
CA2228314A1 true CA2228314A1 (en) 1997-02-20

Family

ID=7768971

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002228314A Abandoned CA2228314A1 (en) 1995-08-08 1996-08-01 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases

Country Status (9)

Country Link
EP (1) EP0843553A1 (de)
JP (1) JP2000501698A (de)
AU (1) AU6702596A (de)
CA (1) CA2228314A1 (de)
DE (1) DE19529102A1 (de)
EA (1) EA199800192A1 (de)
HU (1) HUP0104619A3 (de)
WO (1) WO1997005876A1 (de)
ZA (1) ZA966698B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025969A1 (en) * 1997-07-09 2002-02-28 Wolf-Georg Forssmann Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US6417208B1 (en) * 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
WO2001017480A2 (en) * 1999-09-09 2001-03-15 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2549480B2 (ja) * 1991-12-10 1996-10-30 ヘキストジャパン株式会社 排尿障害改善剤
DE19501482A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one

Also Published As

Publication number Publication date
EA199800192A1 (ru) 1999-06-24
WO1997005876A1 (en) 1997-02-20
DE19529102A1 (de) 1997-02-13
HUP0104619A2 (hu) 2002-04-29
JP2000501698A (ja) 2000-02-15
HUP0104619A3 (en) 2002-06-28
ZA966698B (en) 1998-02-09
EP0843553A1 (de) 1998-05-27
AU6702596A (en) 1997-03-05

Similar Documents

Publication Publication Date Title
US6083483A (en) Inhibitors of phosphodiesterase IV for x-ray imaging
US6391869B1 (en) Compositions and methods for the treatment of anorectal disorders
US6395736B1 (en) Compositions and methods for the treatment of anorectal disorders
US5891904A (en) Use of inhibitors of phosphodiesterase IV
WO2003075851A2 (en) Compositions and methods for the treatment of anorectal disorders
EP1477166A1 (de) Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
CA2295616C (en) Use of phosphodiesterase inhibitors in the treatment of prostatic diseases
US8791124B2 (en) Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US20230414617A1 (en) Pharmaceutical composition comprising acid-base neutralization combination and application thereof
CA2228314A1 (en) Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
DE19540642A1 (de) Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen
JP2022545370A (ja) ウラシル皮膚医薬製剤
WO1997005876A9 (en) Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
DE4230755A1 (de) Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen
DE4338948A1 (de) Verwendung von PDE-Inhibitoren bei der Behandlung erektiler Dysfunktionen
US20080014258A1 (en) Use of fosfluridine tidoxil (FT) for the treatment of intraepithelial proliferative diseases
CN1205634A (zh) 磷酸二酯酶抑制剂在制备用于治疗膀胱疾病的药物中的应用
CA2417848A1 (en) Compositions and methods for the treatment of anorectal disorders
TW200846013A (en) Cytidine derivative-containing antitumor agent for continuous intravenous administration
AU7860394A (en) Use of peniclorin for the treatment of posttherapeutic neuralgia
ZA200104778B (en) Compositions and methods for the treatment of anorectal disorders.
AU2004212586A1 (en) Compositions and methods for the treatment of anorectal disorders

Legal Events

Date Code Title Description
FZDE Discontinued